The International Society for Neglected Tropical Diseases presents ISNTD d3 to address the past shortfalls in R&D productivity and drive the development of future paths towards successful gains in the control, treatment or evaluation of NTDs.
ISNTD d3 will bring together experts from within drug discovery and clinical trials to drive the debate and foster new partnerships & alliances leading to tangible outcomes in terms of new therapies to combat these diseases.
ISNTD d3 also aims to accelerate the networking required for the development & distribution of new or improved drugs, vaccines, microbicides and diagnostics against the NTDs by bringing focus onto the phase II and III clinical trials taking place or set to take place potentially in affected countries.
Eric Chatelain, Head of Drug Discovery, presented on drug discovery and development for Chagas disease.
Q&A: Chagas disease and strategies for disease-specific treatments
Date: May 25, 2016
Chair: Ms Roxanne Khamsi (Nature Medicine)
• Dr Eric Chatelain (DNDi) – Challenges in Chagas Disease R&D